Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Evysion
- Development stage
- Unknown
- Lead developer
- Nanomerics
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
Evysion (OC137) is an investigational ophthalmic formulation developed by Nanomerics for the treatment of retinal degeneration and intermediate age-related macular degeneration (iAMD). It utilizes Nanomerics' proprietary Molecular Envelope Technology (MET), a nanoparticle platform based on modified glycolchitosan, to deliver rapamycin (a small molecule mTOR inhibitor) topically via eye drops. This technology is designed to enable the drug to reach the posterior tissues of the eye, such as the retina and choroid, providing a non-invasive alternative to traditional intravitreal injections. By inhibiting the mTOR pathway, the drug aims to address the underlying mechanisms of retinal degeneration.
- Brand names
- Evysion
- Other names
- Rapamycin MET Eye Drops
Beyond the preview
Go deeper on Evysion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evysion.